by Raynovich Rod | Aug 4, 2016 | Biopharmaceuticals
8/5 After the Close… NASDAQ Up 1.06% The IBB inched up 0.38% to $297.29 while the more volatile XBI did better up 1.07%. Both are still down YTD and trail the QQQ which is up 4.39% YTD. Investors in biotech were not deterred by bad clinical news from...
by Raynovich Rod | Jul 27, 2016 | Biopharmaceuticals
Bullish Tone-Large Cap Biopharmaceutical Earnings Updates 8/5 Regeneron (REGN) shares fell another 2.4% to $423 despite a jump of 23% on Eylea sales to $832M compared to $655 M in the prior-year quarter. Higher expenses cut profitability as GAAP income was up only...
by Raynovich Rod | Jul 21, 2016 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1… Gilead Sciences (GILD) Sells Off on earnings Gilead Sciences (GILD) sold off over 4% after hours after releasing second quarter sales of $7.7B and earnings of $3.08/sh. Q2 profit forecast beat. The full year revenue forecast was also cut slightly by...
by Raynovich Rod | Jul 20, 2016 | Biopharmaceuticals
Biotech Bear Market Rally Headed Toward Triple Top The biotech rally has wobbly legs moving briskly from the Brexit lows but with choppy action recently.This would be the third time biotech stocks will try to gain momentum toward higher highs although lows are...
by Raynovich Rod | Jul 11, 2016 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1… 7/12/16 Dow and S&P Hit Record Highs, Awaiting Q2 Earnings-Risk Still On-Biotech Stocks Lag The market continued its post-BREXIT rally helped by low interest rates and WTI crude up 4.56% to $46.80. Gold eased off and the dollar was up. We are still...
by Raynovich Rod | Jul 5, 2016 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Foundation Medicine (FMI) New Pick at $20.40 We have added Foundation Medicine (FMI) to our core portfolio because of their leadership position in pharmacogenomics and molecular medicine for cancer care. The Foundation One genomic profile helps physicians make...
by Raynovich Rod | Jul 3, 2016 | Biopharmaceuticals
Biopharmaceutical Valuations Look Attractive Sector Poised for Rebound by Year End This is a continuing review of large cap biopharmaceutical valuation metrics to determine which companies can deliver growth from their broad pipelines. The biotech sector has...
by Raynovich Rod | Jun 29, 2016 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-2 …6/30 after the close Biotech stocks rallied again for the third day but momentum ebbed. Large caps were mainly in the green led by Alexion Pharmaceuticals (ALXN), Roche Holding (RHHBY) and Gilead Sciences (GILD). Mid-caps were mixed and well below...
by Raynovich Rod | Jun 22, 2016 | Biopharmaceuticals
6/26…Until the emotion of BRexit subsides there is little to do with trading biotechnology stocks. We need to first see if US healthcare stocks can stabilize so look at XLV which was down 2.94% on Friday to $69.29. Support is at the March 17 low of $66.30. After...
by Raynovich Rod | Jun 17, 2016 | Biopharmaceuticals
Monday June 20… Update 4:30p EDT…BRexit relief rally Biotech stocks pretty much tracked the NASDAQ rally today slowly selling off as the day wore on. The more volatile XBI was still up 1.56% for the day beating the sluggish IBB up 0.91%. The healthcare...
